

Annual General Meeting 21 October 2026





Michael Sammells

Chairman of Sigma

Agenda

1. Chairman and CEO addresses

2. Financial Statements and Reports

3. Remuneration Report

4. Re-election of Directors

5. Remuneration arrangements for key executives

Sigma is a healthcare business with significant scale, capability and market reach, offering defensive earnings characteristics and multiple pathways for long-term growth

**Proudly powering
pharmacy**



Board of Directors



Michael Sammells

Chairman, Non-Executive Director,
Chair of the Related Party
Independent Board Committee



Vikesh Ramsunder

Managing Director and CEO



Dr Christopher (Chris) Roberts AO

Non-Executive Director, Chair of the
Risk, Compliance and Sustainability
Committee



Annette Carey

Non-Executive Director, Chair
of the Nomination and
Remuneration Committee



Neville Mitchell

Non-Executive Director, Chair
of the Audit Committee



Jack Gance

Non-Executive Director



Mario Verrocchi

Executive Director,
CEO – Retail



Damien Gance

Non-Executive Director



Danielle Di Pilla

Executive Director,
Chief People Officer



Strong first full-year performance as a merged group

Earnings grew faster than revenue as scale improves efficiency

\$10.8bn
Revenue


+15.5%

\$1.09bn
Normalised
EBIT

+20.6%

\$605m
FY24 pro-forma
EBIT

FY24 to FY26 EBIT
shows the strategic
logic of the merger



- Balance-sheet discipline: \$663m net debt, equivalent to 0.57× normalised EBITDA.
- Shareholder returns: Total FY26 dividend of 4.0 cents per share, fully franked.

Disciplined growth to build shareholder value



01

Australia

Expand the network and grow like-for-like sales.
Strengthen our network through a three-brand strategy - Chemist Warehouse, Amcal and DDS.

02

International

Enter selected markets with discipline.
Target attractive long-term returns.

03

Brands and products

Differentiate our brands.
Selectively grow own and exclusive labels.

04

Operating leverage

Capture integration and synergy benefits.
Improve supply-chain capacity and efficiency.

Measured UK entry through the Greenlight joint venture from FY27

Investment decisions require a clear strategic rationale and an appropriate return on capital

Related-party protocols



Independent oversight

Dedicated Independent Board Committee (IBC) supported by Working Group

Independent valuations

Independent valuations support related-party property leases.

Ensure consistent and fair arrangements

IBC approval for departures from standard templates or commercial terms, regardless of size

Standard franchise agreements. No preferential founder agreements.

Protecting the interests of all shareholders

ESG progress and community investment



Board accountability

For sustainability strategy and climate-related risks and opportunities

82%

Waste diverted from landfill at Australian distribution centres

5,570 tonnes diverted from landfill

More than \$7.5m

Community investment
Australia and New Zealand

Health and safety

Measures form part of executive performance assessment



Looking ahead





Vikesh Ramsunder

Managing Director and CEO



Growing our network and lifting productivity

Australian growth

15.9%

CW branded store sales growth

24 new stores

18 refurbishments

561 CW stores at 30 June

International expansion

23.3%

CW branded store sales growth

20 new stores

Ireland profitable

Preparing for UK launch

Supply-chain productivity

579m+

Units delivered in Australia

35m more units than last year

Greater scale and automation support operating leverage



Synergy delivery in line with expectations

Delivered progress

\$32.6m

Synergies realised

\$25.9m one-off integration costs

Preston support centres consolidated.

E-commerce DC in Preston closed

Western Australia volume and South Australia volume transferred to Sigma's legacy DC in WA and SA

Next phase

Chemist Warehouse integration into Sigma's SAP platform

Fewer technology applications

Store systems are outside the technology integration scope



FY29 synergies target

\$100m

Per annum synergies

Full realisation anticipated during FY29

Chemist Warehouse trading update



Australian CW branded
store network*

12.1% sales

9.8% LFL sales

International CW
store network#

30.2% sales

15.8% LFL sales

Stores expected to join the network in 1H27

14

Chemist Warehouse
-Australia

42

Amcal and Discount
Drug Stores - Australia

19

International
stores



Chemist Warehouse
Palmerston North, New Zealand

* Financial year to date to 16 October 2026

First quarter of FY27 (to 30 September 2026). International sales reflects constant currency.



Thank you

For more information contact:

Gary Woodford
Head of Corporate Affairs and Investor Relations
gary.woodford@sigmahealthcare.com.au
www.sigmahealthcare.com.au



Important Notice

The information contained in this presentation about Sigma Healthcare Limited and its subsidiaries (Sigma) is designed to provide:

- an overview of the financial and operational highlights for Sigma for the full year period ending 30 June 2026; and
- a high-level overview of aspects of the operations of Sigma, including comments about Sigma's expectations of the outlook for FY27 and future years, as at 21 October 2026.

This presentation contains forward-looking statements relating to operations of Sigma that are based on management's current expectations, estimates and projections about matters relevant to Sigma's future financial performance.

Any forward-looking statements, assumptions, projections, estimates and outcomes contained in this presentation should not be relied upon as a representation or warranty, express or implied by Sigma. They are not an assurance or guarantee of future performance nor should be taken to be, and involve known and unknown risks, uncertainties and other factors which are beyond the control of Sigma in relation to the future business performance or results of Sigma or the likelihood that the assumptions, estimates or outcomes will be achieved.

While Sigma, its officers and management have made every effort to ensure the accuracy of the information in this presentation, this presentation is provided for information only. Neither Sigma, its directors, officers, agents, employees or advisors make any representation, or given any warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the information, forward-looking statements, opinions, estimates, projections, outcomes and conclusions contained in this presentation. Accordingly, to the maximum extent permitted by law, Sigma, its directors, officers, agents, employees and advisors exclude and disclaim any liability, whether direct or indirect, in respect of the accuracy or completeness of the information or any other opinions contained in this presentation or errors, omissions, statements or for any loss, howsoever arising, from anything done in reliance or the use of this presentation.

Sigma assumes no obligation to update or revise any forward-looking statements. Nothing in this presentation constitutes investment advice and this presentation shall not constitute an offer, invitation, solicitation or other recommendation to sell or buy any securities or otherwise engage in any investment activity in Sigma Healthcare Limited. Investors should make their own enquiries and seek their own professional advice (including financial and legal advice) before dealing in securities of Sigma Healthcare Limited.

Due to rounding, numbers presented throughout this presentation may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.